The Fibrotic Diseases Treatment Market Size is valued at USD 3.57 billion in 2023 and is predicted to reach USD 5.40 billion by the year 2031 at a 5.53% CAGR during the forecast period for 2024-2031.
Treatment for fibrotic Diseases aims to manage and decelerate the progression of fibrosis, a condition characterized by the accumulation of extra connective tissue in organs, resulting in scarring and diminished functionality. These disorders can impact multiple organs, including the lungs (as seen in pulmonary fibrosis), liver (hepatic fibrosis or cirrhosis), kidneys, heart, and skin. Therapies for fibrotic disorders seek to diminish inflammation, prevent tissue fibrosis, and tackle underlying etiologies or related conditions.
Treatment options are being increased by ongoing research into innovative medicines such as targeted molecular agents. The need for efficient treatment drugs is anticipated to rise in response to the incresing prevalence of fibrotic disorders, including hepatic cirrhosis, pulmonary fibrotic diseases, renal fibrosis, and cutaneous fibrosis. This is anticipated to propel the fibrotic disease treatment market over the projected period.
Furthermore, since smoking is one of the risk factors for fibrotic disorders such as lung fibrosis and pulmonary fibrosis, the growing number of smokers is anticipated to support the fibrotic disease treatment market. Product introductions, alliances, and mergers and acquisitions will assist the businesses in broadening their geographic reach and range of products offered, which will support the fibrotic disease treatment market's profitable expansion.
The market of fibrotic disease treatment is segmented into treatment, application, end user, & distribution channel. As per the treatment, the market is segmented into Organ Transplantation, Medication, Oxygen Therapy, and Others. By application, the market is segmented into Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Idiopathic Pulmonary Fibrosis, and Others. By end user, the market is segmented into Specialty Clinics, Hospitals, Academic and Research Institutes, and Others. According to distribution channel, the market is categorised into Hospital Pharmacy, Retail Pharmacy, and Others.
The medication category is expected to hold a major global market share in 2023. Fibrotic diseases can be treated with a variety of medications, such as nintedanib and pirfenidone. The category is driven by rising rates of fibrotic diseases, increased R&D efforts to introduce new and creative medicines to the market, and market participants' strategic initiatives that are anticipated to spur the fibrotic disease treatment market expansion throughout the projection period. Research and development efforts have made many new treatment options for a variety of ailments possible. Many medications for the treatment of illnesses have been developed as a result of developing technology developments and relevant research. The drug efficiently heals illnesses and stops their progression.
The market for fibrotic disease treatment is seeing expansion in the hospital sector due to a number of important considerations. Complex fibrotic disorders, like lung fibrosis, liver cirrhosis, and systemic sclerosis, which call for specialist medical care, are largely managed and treated in hospitals. Advancements in diagnostic technologies have resulted in hospitals increasingly employing biomarker-based assays and imaging modalities, facilitating earlier and more accurate diagnoses of fibrotic illnesses. Hospital care volumes have risen due to an aging population, an increase in chronic illnesses, as well as heightened awareness of the significance of early intervention.
The North American fibrotic disease treatment market is expected to record the biggest market share in the near future. Due to the high frequency of fibrotic disorders and the presence of significant industry players, the fibrotic disease treatment market in the region is expanding and providing a good environment for the development of new therapeutics. In addition, Asia Pacific is likely to grow rapidly in the global fibrotic disease treatment market because pulmonary fibrosis is becoming more common and because medical technology has advanced in the industry under study. The introduction of new products and calculated moves by major competitors in the industry will also help the fibrotic disease treatment market expand. Over the course of the projected period, the market is anticipated to rise as a result of the rising prevalence of fibrotic disorders like cystic fibrosis (CF). Additionally, the increased focus on fibrotic disease research and development may result in the release of improved medications, increasing patient access to the treatment.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 3.57 Bn |
|
Revenue Forecast In 2031 |
USD 5.40 Bn |
|
Growth Rate CAGR |
CAGR of 5.53% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment, Application, End-User and Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
AbbVie Inc., Gilead Sciences, Inc., KITHER BIOTECH S.R.L., BioMX, Verona Pharma plc, Genentech, Inc., C.H. Boehringer Ingelheim International GmbH, Redx Pharma Plc, Alpine Immune Sciences, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Camber Pharmaceuticals, Inc., Bristol-Myers Squibb Company, BellBrook Labs, Enveda, Intercept Pharmaceuticals, Inc., Pharmaxis Ltd, and Accord Healthcare |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Fibrotic Diseases Treatment Market Snapshot
Chapter 4. Global Fibrotic Diseases Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Fibrotic Diseases Treatment Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Fibrotic Diseases Treatment Industry Trends
Chapter 5. Fibrotic Diseases Treatment Market Segmentation 1: By Treatment, Estimates & Trend Analysis
5.1. Market Share by Treatment, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Treatment:
5.2.1. Medication
5.2.2. Organ Transplantation
5.2.3. Oxygen Therapy
5.2.4. Others
Chapter 6. Fibrotic Diseases Treatment Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Applications:
6.2.1. Idiopathic Pulmonary Fibrosis
6.2.2. Hepatic Cirrhosis
6.2.3. Renal Fibrosis
6.2.4. Cutaneous Fibrosis
6.2.5. Others
Chapter 7. Fibrotic Diseases Treatment Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channels:
7.2.1. Hospital Pharmacy
7.2.2. Retail Pharmacy
7.2.3. Others
Chapter 8. Fibrotic Diseases Treatment Market Segmentation 4: By End-User Industry, Estimates & Trend Analysis
8.1. Market Share by End-User Industry, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End-User Industrys:
8.2.1. Hospitals
8.2.2. Specialty Clinics
8.2.3. Academic and Research Institutes
8.2.4. Others
Chapter 9. Fibrotic Diseases Treatment Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Fibrotic Diseases Treatment Market, Regional Snapshot 2023 & 2031
9.2. North America
9.2.1. North America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.2.3. North America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.2.4. North America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.2.5. North America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2024-2031
9.3. Europe
9.3.1. Europe Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.3.3. Europe Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.3.4. Europe Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.3.5. Europe Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2024-2031
9.4. Asia Pacific
9.4.1. Asia Pacific Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.4.3. Asia Pacific Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.4.4. Asia Pacific Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
9.4.5. Asia Pacific Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2024-2031
9.5. Latin America
9.5.1. Latin America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.5.3. Latin America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.5.4. Latin America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.5.5. Latin America Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2024-2031
9.6. Middle East & Africa
9.6.1. Middle East & Africa Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.6.3. Middle East & Africa Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.6.4. Middle East & Africa Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.6.5. Middle East & Africa Fibrotic Diseases Treatment Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Genentech, Inc..
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial PerTreatmentance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. AbbVie Inc.
10.2.3. Accord Healthcare
10.2.4. Alpine Immune Sciences
10.2.5. BellBrook Labs
10.2.6. BioMX
10.2.7. Bristol-Myers Squibb Company
10.2.8. C.H. Boehringer Ingelheim International GmbH
10.2.9. Enveda
10.2.10. Gilead Sciences, Inc.
10.2.11. Intercept Pharmaceuticals, Inc.
10.2.12. KITHER BIOTECH S.R.L.
10.2.13. Pharmaxis Ltd
10.2.14. Redx Pharma Plc
10.2.15. Sandoz International GmbH
10.2.16. Teva Pharmaceutical Industries Ltd.
10.2.17. Verona Pharma plc
10.2.18. Camber Pharmaceuticals, Inc.
10.2.19. Other Prominent Players
Fibrotic Diseases Treatment Market By Treatment-
Fibrotic Diseases Treatment Market By Application-
Fibrotic Diseases Treatment Market By End User-
Fibrotic Diseases Treatment Market By Distribution Channel-
Fibrotic Diseases Treatment Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
